P/E ratio for LabCorp (LH)
P/E ratio as of May 2024 (TTM): 28.1
According to LabCorp's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 28.0851. At the end of 2022 the company had a P/E ratio of 16.9.
P/E ratio history for LabCorp from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | 16.9 | 32.24% |
| 2021 | 12.8 | 0.17% |
| 2020 | 12.8 | -36.48% |
| 2019 | 20.1 | 38.49% |
| 2018 | 14.5 | 12.69% |
| 2017 | 12.9 | -29.3% |
| 2016 | 18.2 | -36.37% |
| 2015 | 28.6 | 60.04% |
| 2014 | 17.9 | 25.8% |
| 2013 | 14.2 | 0.27% |
| 2012 | 14.2 | -14.32% |
| 2011 | 16.5 | 2.4% |
| 2010 | 16.2 | 10.41% |
| 2009 | 14.6 | -3.89% |
| 2008 | 15.2 | -17.95% |
| 2007 | 18.6 | -11.85% |
| 2006 | 21.1 | 13.37% |
| 2005 | 18.6 | -3.09% |
| 2004 | 19.2 | 16.16% |
| 2003 | 16.5 | 27.05% |
| 2002 | 13.0 | -58.41% |
| 2001 | 31.2 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 IDEXX Laboratories IDXX | 52.6 | 87.23% | 🇺🇸 USA |
 Quest Diagnostics
DGX | 20.6 | -26.70% | 🇺🇸 USA |
 Translate Bio
TBIO.defunct | N/A | N/A | 🇺🇸 USA |
 NeoGenomics
NEO | -16.7 | -159.60% | 🇺🇸 USA |
 Qiagen QGEN | 31.2 | 11.14% | 🇳🇱 Netherlands |
 Enzo Biochem ENZ | -1.16 | -104.13% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.